|Day Low/High||45.01 / 45.80|
|52 Wk Low/High||27.88 / 43.08|
Investors should watch Asian vaccination rates for a guide to the continent's economic rebound.
What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?
This week will tax your brain. Your ability to focus on what really matters will be tested.
But remember I think it's all a snag and one that will be rectified in two ways.
It would not be surprising to see this seesaw action repeatedly in the months ahead.
Also, there's reason to turn J&J's one shot jab into a two shot vaccine just like the rest.
Just as fears of Fed tightening and a trade war created buying opportunities in tech and elsewhere in late 2018, arguably overblown fears about the Delta variant's economic impact are creating opportunities now.
Traders could go long PFE at current levels and here's where they can add to longs.
Plus, China's central bank plans to cut its Reserve Ratio Requirement and Wells Fargo looks to exit a business line.
Contrary to popular belief, this economic recovery that we seem to be enjoying has hit a pressure point.
These companies were counted out way too early in the post-pandemic environment and the sellers are experiencing some real regret.
Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.
There's a split growing at the FOMC as to just how transitory the current burst of consumer level inflation actually is.
Here's what Jim Cramer expects to hear from GSK at this week's investor meeting.
CVAC is now working on a 'next generation' COVID-19 vaccine candidate with GlaxoSmithKline.
The public seems to have resigned itself to dealing with a greater degree of inflation for longer than anything I would have considered to be 'transitory.' The again, the public is often as wrong as the Fed.
I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.
How long have we cried out in the wilderness with no one listening? Finally, perhaps, a champion has risen from the depths.
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.
After a pretty solid two year note auction - tightly anchored by the fed funds rate expectations - today's 5 year was very good too. The yield of 0.788% was about ½ bp below the when issued. The bid to cover of 2.49 was better than the 12 month aver...
Last year's top-performing stock market worldwide has been a disappointment since setting an all-time high in February. Could it have just turned?
We've been caught with our pants down, largely because we had no faith in the smartest people in the country.
The market seems to rejoice from the latest mask utterance out of the CDC, but the action at the Nasdaq should give traders pause.
ARCT's IP is incredibly valuable, and may in fact be invaluable.
The market came within whiskers of a technical breakdown on Thursday, yet few people seem to know or care.
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.